Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

To watch more expert insights and analysis ... Pfizer, as it competes with the likes of Novo Nordisk and Eli Lilly in the weight loss drug space. 00:43 Speaker B Plus, Nvidia announcing a big ...

A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new ...

Brad Smith and Madison Mills take a closer look at some of today's trending tickers. Pfizer (PFE) discontinued its obesity ...

Pfizer has announced that it is discontinuing ... We sell different types of products and services to both investment professionals and individual investors. These products and services are ...

Its statement also suggested the patient’s liver enzymes were elevated. That often is indicative of damage to cells in the organ, according to the Cleveland Clinic. Pfizer told CNBC that the trial ...

And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls ... new medicines to patients,” Pfizer’s Chief Scientific Officer ...

We sell different types of products and services to both investment professionals and ... unvarnished thinking of our people and exacting analysis of our research processes. Our authors can ...

Factors driving the market include rising disease prevalence, innovative therapies, and gene-based treatment breakthroughs. Key players like H Lundbe ...

The COVID-19 vaccine continues to save lives, proving the vaccination strategy paid off and was a worthwhile national ...